Markets:

Overview

News

Currencies

International

Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

35.90 +0.05 (+0.15%)

Streaming Delayed Price Updated: 9:30 AM EST, Dec 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

October 18, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio ↗

September 27, 2023

Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023 ↗

September 14, 2023

Via Benzinga

Analyst Ratings for RAPT Therapeutics ↗

September 14, 2023

Via Benzinga

The Latest Analyst Ratings for RAPT Therapeutics ↗

August 09, 2023

Via Benzinga

Analyst Ratings for RAPT Therapeutics ↗

June 05, 2023

Via Benzinga

RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September

August 30, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Reports Second Quarter 2023 Financial Results

August 11, 2023

Company maintains strong cash position of $205 million

From RAPT Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023 ↗

August 09, 2023

Via Benzinga

Analyst Expectations for RAPT Therapeutics's Future ↗

May 12, 2023

Via Benzinga

Recap: RAPT Therapeutics Q1 Earnings ↗

May 11, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 ↗

June 15, 2023

Via Benzinga

RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference

June 07, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers

May 25, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

The Latest Analyst Ratings for RAPT Therapeutics ↗

March 15, 2023

Via Benzinga

RAPT Therapeutics Reports First Quarter 2023 Financial Results

May 11, 2023

Company maintains strong cash position of $231.6 million

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

May 03, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

April 26, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 17, 2023

Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.

Via Benzinga

Why Marpai Shares Are Trading Lower By 26%; Here Are 20 Stocks Moving Premarket ↗

April 17, 2023

Gainers CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) jumped 153% to $5.96 in pre-market trading after jumping 243% on Friday.

Via Benzinga

Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

April 17, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93...

Via Benzinga

RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma

March 29, 2023

From RAPT Therapeutics, Inc.

Via GlobeNewswire

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

S&P 500 Rises 1%; Crude Oil Down Over 4% ↗

March 14, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 1.5% on Tuesday. The Dow traded up 0.40% to 31,945.39 while the NASDAQ rose 1.58% to 11,365.53. The S&P 500,...

Via Benzinga

Dow Extends Rebound, Surges 456 Points ↗

March 14, 2023

Rallying bank stocks are fueling Wall Street's midday gains, as investors continue to unpack this morning's consumer price index (CPI) data.

Via Talk Markets

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 14, 2023

Via Benzinga

Nasdaq Jumps Over 200 Points; GitLab Shares Plummet ↗

March 14, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 400 points on Tuesday. The Dow traded up 1.30% to 32,234.35 while the NASDAQ rose 2.07% to 11,421.23. The S&P 500,...

Via Benzinga

Dow Surges Over 300 Points; US Inflation Rate Drops To 6% ↗

March 14, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded up 1.03% to 32,145.42 while the NASDAQ rose...

Via Benzinga

Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 14, 2023

Gainers Ainos, Inc. (NASDAQ: AIMD) shares jumped 69.3% to $1.27 after the company announced it signed a Memorandum of Understanding with Merdury Biopharmaceutical to jointly explore and develop a...

Via Benzinga

RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results

March 14, 2023

Company maintains strong cash position of $249.1 million

From RAPT Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.